Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Calm68, you nailed it. One would think given the background and expertise of our corporate advisors, they have done a little DD not only on the science, but on the market opportunities that exist. This is done by talking to researchers and medical professionals who are actually in practice in the field of medicine. Compare those results to the contradicting opinions posted here.
Zoom, are you seriously suggesting the experts at the Alzheimer's Association know what they're talking about? Their statements directly contradict the experts posting on this board who claim there is no market for a AD diagnostic test.
We should all sell our shares now before LymPro results in a huge failure with zero sales. Fire all the researchers who are clamoring for this test to screen their AD trial subjects to more effectively test possible cures in human trials. They obviously aren't as well versed in the expected demand for the LymPro test as the experts on this board.
What's next? Are you going to suggest that MANF is a possible curative treatment for Parkinson's Disease, Retinitus Pigmentosa, Wolfram's Syndrome, TBI, Diabetes, etc?
I'm so confused... which experts do I believe? Those who are actively conducting research or advising companies who are moving towards commercial success, or those who sit at their keyboard all day typing long posts on a message board, unaware that most readers have them on ignore?
LOL
Oh yes, then this board would be vastly more entertaining, as they would directly challenge the posted statements of some of our resident medical experts, and that might actually lead to the revelation that some of the posters here don't really know what they're talking about.
I'm with you. Given their extensive backgrounds of John C and the advisory board in key areas specific to our assets, I would trust their opinions and their knowledge a great deal more than some random message board poster who claims extensive medical knowledge yet seems to get a number of things wrong in these key areas.
'Nuff said about that.
Back when Gerald set up Amarantus as a holding company and split the company into therapeutic and diagnostic divisions, he stated it was done as a strategic move so future transactions in one division would have no impact on the other division. He's also stated that he wears many hats, and that eventually the company will bring in someone to run the diagnostics division while he runs the therapeutic division.
Given the rapid growth and recent additions of assets within the diagnostics division, one possibility that comes closer to reality is a spinoff or sale of the diagnostics division. This could provide hundreds of millions of dollars to Amarantus to continue their work with MANF in the therapeutics division. Also, John Commissiong's statements in the recent CEO blog The Golden Goose: Preparing PhenoGuard to Lay the Next Golden Egg make it clear he is eager to return to discovering new neurotrophic factors. This is his passion... a true scientist, and highly respected in the field of neurology.
http://www.thechairmansblog.com/amarantus-bioscience/john-commissiong/golden-goose-preparing-phenoguard-to-lay-the-next-golden-egg/
While the diagnostics division is geared to provide the initial revenues to the company, a sale of this division would provide an immediate, massive cash influx to drive what is considered to be the real Golden Goose for the company.... the neurotrophic factors discovery and commercialization. It certainly seems like Gerald has been working overtime to significantly boost the value of the diagnostics division. Is that a precursor to a sale or spinoff of that division to fund his father's passion? It certainly seems like a distinct possibility to me.
To give credit where credit is due, I spoke with JPetro earlier today, and we discussed this possibility, and many of the thoughts I posted here are his thoughts and insights. Perhaps he can add more insight in areas I might have overlooked in this post.
Interesting times ahead, that's for sure. I'm glad to be an Amarantus investor in these early stages.
Agreed, nice dip. My brother-in-law just picked up another 50K shares on the dip. He's already tripled his money on his previous shares.
Like me, he understands that LymPro doesn't detect anything moving through the blood-brain barrier, so that is not a limitation as some have attempted to portray. Again, doing one's own DD will easily reveal this. It's all covered in the LymPro white paper on the Amarantus web site, and also was discussed by Gerald at one of the earlier conferences. Gerald was specifically asked about the blood-brain barrier related to the LymPro blood test.
We also understand that GDNF was proven to drastically reduce the effects of PD with actual patients, and that GDNF just happens to be a neurotrophic factor, which directly dispels uninformed claims that NFs have proven ineffective in PD. Perhaps someone didn't see the remarkable video of these patients who were being treated with GDNF.
And finally, we both understand that both GDNF and MANF have proven effective in rat models of PD, and since GDNF has also proven effective in humans, MANF is expected to prove effective as well, even more so given the improved response in the rat model of PD. It appears the method of simulating PD in rat brains by lesioning the brains to simulate damage from PD is not impacted at all by the alpha sun claims. The same positive behavioral results of reduced PD symptoms observed in the rat models were also observed in humans.
With the number of assets in the Amarantus pipeline, and the experience of our advisors guiding management, I see the timeline being much shorter for Amarantus, as compared to Amgen. 10 years is likely to be more than enough considering their fast-track orphan strategy leading to reduced regulatory hurdles.
Great to hear, jacmar. I'm sure you're smiling every quarter when those AMGN dividend checks are rolled into buying more AMBS shares... the tickets to your 2nd once-in-a-lifetime investment opportunity.
Hopefully we'll be in the same situation one day with Amarantus. I can only imagine what those quarterly dividend checks will look like, given the market potential of MANF once it's realized, not to mention the enormous share price.
GLTY
Amarantus CEO intends to up-list to a national exchange Apr-Jun 2014.
http://www.onemedplace.com/onemedtv/play.php?vid=2548 (30 seconds into the presentation)
Just imagine the catalysts to be unveiled prior to this up-list. Gerald has stated numerous times there are catalysts coming that will significantly increase shareholder value.
If you've done your DD and believe in the science, believe in the quality of our management, and the quality of the expert advice given to management from the World-Class advisors they've assembled...
...then buy shares and hang on for the investment ride of a lifetime.
Ignore the self-proclaimed experts who suggest otherwise and try to create ethical issues where none exist. Do your own DD and draw your own conclusions. It's well worth the effort, and the time spent could lead to enormous financial rewards in this investment.
Short selling isn't offensive to me, nor are those who trade part or all of their positions. I understand there are different types of investors. What is offensive are those who flip and post positive and negative comments about the company, their management, their advisors, or the science... based on which side of the flip they're currently on. The constant twisting of facts to support one's own agenda is pretty obvious as well. They all know who they are, as do the rest of us. Seems like a lot of time wasted doing that, as the only ones who will be influenced are new investors and those who haven't done their own DD.
A prime example is taking one sentence out of a presentation and interpreting it to mean only one thing, while ignoring all of the other evidence that points to different interpretation. This is similar to those who take a single verse out of the Bible and use it to reach a conclusion, while ignoring the supporting verses and context in which the verse is written, which often provide a different meaning to the verse.
That, in my view, is a pretty sad and despicable way to express oneself as a human being.
As a long-term investor myself, I'm looking at the long-term trend. Like many investors here, I feel we've come across a once-in-a-lifetime investment opportunity with Amarantus, and no amount of misinformation and personal agendas will shake my shares from my hands.
Still in the green here by $446K with $millions$ more to come. I know that must upset some who still believe that "most" investors are still underwater. Everyone I know personally who is invested here is well above water. LMAO
Bleckman is not "JackedOnCaffeine". Great deductive reasoning there, Sherlock. I seem to remember some other claims of posters being Bleckman, conclusions also reached with the same deductive reasoning skills (or lack thereof).
Please link us to anything that indicates FBI involvement. Perhaps my memory fails me, but I certainly don't recall FBI being involved. SEC yes, but not FBI. You might want to contact your pal CT on this.
I also don't recall IRS being involved in any investigation of the company, other than their involvement AFTER the company self-identified the payroll tax issue and voluntarily reported it to the IRS. I'm sure the IRS examined the affected payroll records after this was reported, but this isn't the same as launching an investigation of the company. Again, please provide links to anything that indicates an IRS investigation.
Or are all of these claims "in your opinion"?
I read your post and I understood it when I responded. If you watched the video, you would see there is plenty of evidence to support naked shorting happening in not only listed stocks, but penny stocks as well. The Global Links example I referenced is a penny stock. The investor bought up all 1.1MM shares and yet 50MM shares continued to trade over the next 2 days. Seems someone was shorting a penny stock there, to an enormous degree. And in most of the cases presented, they were able to document that the big price drop in the stock occurred at the same time as a huge increase in short positions, and the stocks were on the Reg SHO list for exceeding the threshold of FTD trades.
I guess it was the "pretty much an urban myth" and "phantom info" and "virtually no one shorts a penny stock" and "until you can produce the actual supposed naked short numbers (which is impossible)" parts that led me to respond. I get your point that investors always jump to the naked shorting reason to explain the decline in their stock's price, but my point is that the practice does exist and it has destroyed a lot of companies. Even the authors of the SEC regulations regarding this acknowledge it is happening, and one of them was interviewed in the documentary, as well as statements from SEC officials and Congress concerning the problem.
If Rubinfeld was participating in EPO and responsible for the problems that followed... then why was his name never brought up in the litigation? Surely the prosecutors weren't stupid enough to let a culprit like Rubinfeld escape with no punishment.
Answer: Because he wasn't involved except possibly during the early stages, during the 3 years he was part of Amgen. EPO continued with clinical trials for years after he left.
I suppose there was a conspiracy among the courts, prosecutors, Amgen management, and everyone involved to keep Rubinfeld's name out of it, right? LMAO
Pagan, naked shorting is not an urban myth. Sorry for responding to a post you made 2 months ago, but I seldom visit the WSGI TA board these days, and that post happened to catch my eye.
Watch the Bloomberg documentary "Phantom Shares". In particular, go to the 9:00 minute point and watch the story of Global Links, where a single investor purchased all 1.1MM of the outstanding shares of the company and watched as 50MM shares continued to trade. There is no other explanation except naked short selling. This is not someone's opinion. This is documented.
http://vimeo.com/42321845
The experts in the documentary who try to downplay naked shorting as an insignificant portion of the overall trades is missing one key point. Naked shorting of a single company can destroy or seriously damage a company's value. It might be an insignificant part of the trades in the overall market, but it is very significant to the targeted companies where it's being practiced.
A similar argument would be that if I print counterfeit $20 bills, but I only produce 5000 of them, that's an insignificant portion of the many millions of $20 bills in circulation, so no one should be concerned, right? Tell that to the merchants who accept my counterfeit bills. Tell that to the Feds who will lock me up for creating even a single fake $20 bill. Why isn't the same level of concern placed on naked short selling? It's counterfeiting as well.
I'm not making the claim that naked shorting is to blame for WSGI's share price. I'm stating that it does exist, and there's clear evidence to support this.
Joseph Rubinfeld left Amgen in 1983, and as far as I can tell had no further involvement, as he pursued founding and advising other companies.
Sorry, I have to disagree. The progress chart has been on their website for as long as I've been an investor, all the way back to Dec. 2012. And there have always been 2 of the diagnostics in Phase II, LymPro and NuroPro for PD. I have pointed out that chart to other potential investors and have answered questions about it.
Anyone else remember how far back this chart has been on the Amarantus website?
http://www.amarantus.com/diagnostic-development/diagnostics
That's what the company website has shown for the status of NuroPro since their initial licensing, if I recall correctly.
http://www.amarantus.com/diagnostic-development/diagnostics
Great DD, Hillbilly. I'm also of the belief that MJFF is not done with Amarantus, far from it. When the first grant arrives, watch the backpedaling begin from those who have claimed MJFF has "washed their hands" of Amarantus. LOL
More statements not supported by facts.
What does this post have to do with Amarantus or any of their physicians/advisors? It seems to be OFF TOPIC.
Those were NOT the words of Gerald, and is not a direct quote. I don't understand why this claim continues to be made, even in the face of direct evidence to the contrary.
Here's my proof, which begins at the 12:25 minute point when Gerald begins updating the conference about MANF. Note Gerald NEVER says that MANF for PD is "on hold", but does say "were still continuing to pursue".
http://www.iradeo.com/warpcore61/player/113471
The CED data being generated and expected in 1H 2014 is clear evidence progress is continuing toward PD with MANF. It is my understanding the CED data is a necessary step in the progression (key word) towards primate trials with MANF for treatment of PD, and CED will be used with the primates. In the original Amgen trials, GDNF was administered to the primates and humans using the same delivery method for both. CED is a vast improvement over the earlier method, and it is hoped the improved method will eliminate the problems encountered with the GDNF delivery method used by Amgen back in the 1990s.
I agree progress in this area has slowed as orphans have taken priority, but progress is not on hold. Also, it has been clearly stated by Gerald and his advisors that the orphan strategy will shorten the regulatory pathway for MANF in PD, so the orphan development in itself is progress in MANF for PD. Any post claiming this is on hold is simply wrong and is not supported by the facts.
Which one? Where is there evidence of their involvement? This article mentions nothing about who was involved. I suppose we're just supposed to take the poster's word for it?
Involvement doesn't constitute guilt. They could have been called as material or expert witnesses, or their involvement may have been without knowledge of what others were doing that violated ethics or the law.
I would expect Amarantus to do considerable background checks before bringing on a corporate advisor or board member. Perhaps your concerns should be addressed to the Amarantus board, assuming there's more evidence that proves their specific involvement or guilt. Unfortunately, they will probably rely on the findings of the courts and medical review boards, so it sounds like this approach won't have any impact.
So this is how medicine works? The medical boards routinely take out the whistleblowers by revoking their medical licenses... and this has nothing to do with their demonstrated incompetence to practice medicine, their unprofessional conduct in the practice of medicine, their failure to corporate with the medical board's investigation, or their refusal to corporate with the board's requirements to have their medical license reinstated. It's all simply retaliation for blowing the whistle?
Wow, who would have thought? With all these medical boards around the country conspiring to screw the whistleblowers, one has to be pretty frightened about the quality of medical professionals who still practice medicine. This conspiracy could be as big or bigger than the faking of the moon landings, or the CIA taking out Kennedy and blaming it on Oswald. Maybe Elvis IS still walking among us. I saw a headline on the Enquirer last week while checking out at the grocery store that said, "ELVIS Spotted in New Orleans Brothel". I suppose there might be a sliver of truth in that. What's your opinion?
My dictionary defines it this way. There are many definitions and many contexts, only the applicable one related to status of something is listed.
hold: [with obj.] prevent from going ahead or occurring: hold your fire!
PHRASES on hold
• waiting to be connected while making a telephone call.
• temporarily not being dealt with or pursued: he put his career on hold.
Nowhere in the definition or the other contexts is there any reference to a slowing of progress. So I don't see this as being open to someone's interpretation. If someone's understanding of the definition of the term is wrong, then their conclusion based on that term is wrong. Period. The accuracy of their conclusion is based on the definition, not on their interpretation.
I'm reposting the links from my earlier post, which was deleted.
Here's Slide #6 from the presentation. Notice the last bullet item under MANF. Clearly if CED delivery data with Renishaw is expected in first half of 2014, then progress is continuing towards MANF for PD, since CED is the delivery mechanism to the brain. I expect the CED method of MANF delivery will be used in the upcoming primate trials and that's why the CED data is relevant now. Putting something on hold means work and testing is halted, to resume at a later time. Clearly that's not what's happening here.
Here's the audio clip from the presentation where Gerald begins to talk about MANF. He clearly states that progress is continuing with MANF for PD (which also coincides with what is shown on the slide above), and is word-for-word what I stated in a previous post.
MANF for PD
That's my understanding as well, r00kie. I have looked into their backgrounds, and found none who had their licenses to practice medicine revoked, either for misconduct or incompetence. They are currently practicing medicine or conducting medical research.
I'm quite sure Amarantus wouldn't be interested in working with advisors who had their medical licenses revoked, whatever the reason. MJFF likely wouldn't see that in any positive light when reviewing their grant application package.
joboggi, your post stated that MANF for PD was on hold. It is not on hold. It may be delayed a bit because primary focus is on orphans involving MANF, but work is still continuing on MANF for PD. I posted clear evidence to this fact.
And for the record, your post was NOT word-for-word what Gerald stated. Mine was. Anyone listening to the full presentation or to the specific segment in question (using my link) can hear this for themselves.
I ask other posters to chime in here and give their opinion on whether MANF for PD is on hold, based on the evidence already submitted here.
Is MANF for PD on hold, or is progress continuing?
Agreed. My example was with an existing fuels company, not a company just entering the business. The credit and payment system might not be the same in this scenario, but as you stated, this would be worked out to accommodate everyone involved. Once the business is going, the model could change to align with the existing fuels companies.
Not really interested in investing here, but still take a look every so often, and I sincerely hope it works out for you and the other shareholders. I saw a couple of posts where I thought I might add something of value to the readers.
Your assumption might be correct. I don't know how other fuel distributors work. I only know how it works in my brother-in-law's company. But from my observations, fuel loads move pretty fast, especially in a high volume station, so it's not like they'll be waiting months for payment. More likely a couple of weeks at most, assuming the loads are ordered and paid for as described in my previous post.
Yeah, the bouncing elephant is cool. There's an entire video that clip is captured from, where the elephant is not only bouncing on the trampoline, but also doing flips and rolls while airborne. I'm guessing you understand what my signature is about, from my interactions on the other board where I'm invested. LOL
The sale can be reported with a signed purchase contract. This amount would show up on the books in Accounts Receivable. Revenue wouldn't be recorded until actual payment has been received by the company, and the amount would be cleared off A/R and added to Cash.
One of my relatives works for a fuels company, and if their customers are in good standing with their credit, they order and receive a load of fuel, and have up to 30 days to pay for it. They typically operate for a week or two on a single load, and once they have the income generated for the load, they pay for the load.
If they have a customer who doesn't pay in a timely manner, or owns multiple gas stations and has an excessive number of loads bought on credit, they require payment up front for any new loads until payment for the existing loads has been received. In other words, there's a credit limit determined for each customer, and no new loads are delivered if the credit limit is reached.
I think he stated that 95% of their customers pay on time and they have a good relationship with the company.
Is 0.089 the price for selling those 8 million AMBS shares? I hope it's understood we can look at the trades to verify this, so posters should be careful when making bogus claims.
Gerald's AMBS stock purchase history
Source: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001566928
These are Gerald's purchases only, and do not include the shares and options he was awarded as CEO. This proves Gerald is NOT underwater as some uninformed posters have claimed.
Nice to see Gerald in buying mode again, giving a clear signal to investors the direction he thinks his company is headed.
Perhaps a little better DD is required. Gerald's Form 4 purchases are pretty easy to find, and many here already realized that Gerald is NOT underwater on his shares.
I'm not underwater, far from it. I know quite a number of investors who invested after I introduced them to Amarantus. Everyone I know who has invested here has at least doubled their investment in value. I can only imagine how much their investment will grow in the coming months and years.
Very smart move. Remember, you will have until April 15, 2015 (or October 15, 2015 with extension) to reverse this if AMBS fails to perform as expected. I don't see that as being very likely, but the safety net is there if needed.
Good job picking up more shares on Thursday's panic selling. Selling shareholders either didn't understand the magnitude of Gerald's closing statements at the conference, or they were betting on a partnership announcement this week, and decided to bail when they learned any LymPro partnership will be delayed. I believe that was a mistake on their part. When the eventual partnership is announced, it's likely to catch them off guard, and if not already reinvested, they'll be chasing the price up on huge demand.
Loving AMBS here too. Been a shareholder since late 2012, with initial purchase at 2.5 cents and adding more over the coming months. By far the best investment potential I've ever seen. Their management and board of advisors are top notch, and multiple product lines make this a promising and less risky investment than many biotech companies at this stage.
Yes, I've spent some time in King's Bay. My sub was the USS John C. Calhoun (SSBN-630). Home port was King's Bay, but I lived in Charleston. I served on the "Johnny C" from 1984 to 1988, although the first 1.5 years of that time was in the Charleston Naval Shipyard for refit/overhaul/refueling. That was some of the hardest work I've ever done in my life... at least it was for us "nukes".
When were you in King's Bay, and what were you doing there?
The ride to success as an Amarantus investor is likely to be a bumpy one. If you look at Amgen's price history, you'll see the same bumpy road. I've found it often helps to get away from monitoring the share price and just focus on the news. As long as the company continues to hit their goals, the share price will eventually follow.
It also helps to try to remove oneself from the investor mentality, and focus on the science and how the products they are developing will benefit millions of people around the world. I think we are very fortunate to have the father and son team with so much talent and drive, living modest lives, but passionate about moving the science forward to help others. Yes, they'll make a lot of money if successful, but it's clear to me and many others that money isn't their primary goal.
Things are unfolding for this to be a GREAT year for shareholders. Stay the course, and try to enjoy life with the limited time we all have.
GLTY